Grifols manufactures and markets plasma-derived medicines to treat chronic and acute conditions in the therapeutic areas of immunology, pulmonology, hematology, thrombolytics and neurology.
Employment range in NC
Primary site activity
Potential end market(s)
Products on market
Gamunex-C, PROLASTIN-C, Plasbumin,GamaSTAN, HyperHEP B, HyperRHO, HyperRAB, HyperTET, Plasmanate, Koate - DVI, Thrombate III
Products under development
Pipeline development areas include: Thrombolytics, Pulmonary, Immunology, Hematology, Neurology